Huntington National Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.8M Sell
27,754
-1,369
-5% -$607K 0.07% 189
2026
Q1
$13M Sell
29,123
-3,876
-12% -$1.81M 0.07% 192
2025
Q4
$15M Buy
32,999
+3,552
+12% +$1.53M 0.09% 158
2025
Q3
$11.5M Sell
29,447
-3,965
-12% -$1.66M 0.07% 183
2025
Q2
$14.9M Sell
33,412
-2,356
-7% -$1.09M 0.1% 152
2025
Q1
$17.3M Sell
35,768
-2,618
-7% -$1.22M 0.13% 142
2024
Q4
$15.5M Sell
38,386
-843
-2% -$391K 0.11% 149
2024
Q3
$18.2M Sell
39,229
-1,118
-3% -$537K 0.13% 142
2024
Q2
$18.9M Sell
40,347
-5,850
-13% -$2.54M 0.15% 138
2024
Q1
$19.3M Sell
46,197
-20,632
-31% -$8.72M 0.16% 137
2023
Q4
$27.2M Sell
66,829
-52,806
-44% -$19.5M 0.25% 102
2023
Q3
$41.6M Buy
119,635
+7,616
+7% +$2.66M 0.42% 67
2023
Q2
$39.4M Buy
112,019
+102,249
+1,047% +$34.5M 0.37% 74
2023
Q1
$3.08M Buy
9,770
+5,611
+135% +$1.68M 0.03% 267
2022
Q4
$1.2M Buy
4,159
+560
+16% +$171K 0.01% 359
2022
Q3
$1.04M Sell
3,599
-118
-3% -$34K 0.01% 363
2022
Q2
$1.05M Sell
3,717
-361
-9% -$96.6K 0.01% 371
2022
Q1
$1.06M Sell
4,078
-209
-5% -$49.6K 0.01% 382
2021
Q4
$941K Sell
4,287
-1,026
-19% -$200K 0.01% 400
2021
Q3
$962K Sell
5,313
-441
-8% -$86.1K 0.01% 386
2021
Q2
$1.16M Buy
5,754
+4,746
+471% +$993K 0.01% 362
2021
Q1
$217K Buy
1,008
+39
+4% +$8.57K ﹤0.01% 506
2020
Q4
$229K Sell
969
-613
-39% -$141K ﹤0.01% 476
2020
Q3
$431K Sell
1,582
-122
-7% -$33.7K 0.01% 386
2020
Q2
$495K Sell
1,704
-26
-2% -$7.05K 0.01% 373
2020
Q1
$411K Buy
1,730
+580
+50% +$133K 0.01% 384
2019
Q4
$253K Buy
1,150
+548
+91% +$111K ﹤0.01% 488
2019
Q3
$102K Buy
602
+31
+5% +$5.48K ﹤0.01% 649
2019
Q2
$106K Buy
571
+6
+1% +$1.05K ﹤0.01% 655
2019
Q1
$104K Sell
565
-210
-27% -$38.8K ﹤0.01% 673
2018
Q4
$128K Buy
775
+112
+17% +$19.4K ﹤0.01% 595
2018
Q3
$128K Buy
663
+230
+53% +$41K ﹤0.01% 654
2018
Q2
$73K Sell
433
-379
-47% -$58.7K ﹤0.01% 824
2018
Q1
$132K Buy
812
+347
+75% +$56.7K ﹤0.01% 672
2017
Q4
$70K Sell
465
-16
-3% -$2.37K ﹤0.01% 881
2017
Q3
$73K Buy
481
+212
+79% +$31.9K ﹤0.01% 872
2017
Q2
$35K Buy
269
+225
+511% +$27.1K ﹤0.01% 1034
2017
Q1
$5K Buy
+44
New +$3.87K ﹤0.01% 1267
2016
Q4
Sell
-30
Closed -$3K 1520
2016
Q3
$3K Hold
30
﹤0.01% 1419
2016
Q2
$3K Sell
30
-50
-63% -$4.32K ﹤0.01% 1393
2016
Q1
$9K Sell
80
-74
-48% -$6.69K ﹤0.01% 1485
2015
Q4
$19K Buy
154
+22
+17% +$2.66K ﹤0.01% 1251
2015
Q3
$14K Buy
132
+32
+32% +$4.11K ﹤0.01% 1366
2015
Q2
$12K Buy
100
+20
+25% +$2.52K ﹤0.01% 1465
2015
Q1
$9K Buy
80
+8
+11% +$959 ﹤0.01% 1495
2014
Q4
$9K Buy
+72
New +$8.11K ﹤0.01% 1469
2014
Q1
Sell
-402
Closed -$30K 1542
2013
Q4
$30K Buy
402
+1
+0.2% +$70 ﹤0.01% 1239
2013
Q3
$30K Sell
401
-56
-12% -$4.46K ﹤0.01% 1211
2013
Q2
$37K Buy
+457
New +$33.7K ﹤0.01% 1135

Other funds holding VRTX

Huntington National Bank's VRTX Position: Q2 2026 in Review

Huntington National Bank reduced its Vertex Pharmaceuticals (VRTX) stake by 4.7% in Q2 2026, selling an estimated $607K and leaving 27,754 shares worth $13.8M. The position accounts for 0.07% of the portfolio, ranked #189.

Huntington National Bank first reported a position in VRTX in Q2 2013 and has held it in 49 quarters since. The position peaked at $41.6M in Q3 2023. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Huntington National Bank held 27,754 shares of Vertex Pharmaceuticals worth $13.8M as of Q2 2026.
  • Huntington National Bank sold 1,369 Vertex Pharmaceuticals shares in Q2 2026, an estimated $607K.
  • Vertex Pharmaceuticals made up 0.07% of Huntington National Bank's portfolio in Q2 2026, its #189 holding.
  • Huntington National Bank first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • Huntington National Bank's Vertex Pharmaceuticals position peaked at $41.6M in Q3 2023.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.